This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  

This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.  

At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, presented his research regarding patient perspectives on fatigue management in prostate cancer. In this follow-up interview, he elaborates on the current lack of information geared toward patients experiencing fatigue while receiving novel hormonal agents and his goal of creating guidance to fill this gap.